Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 84, 184-192
- https://doi.org/10.1016/j.ejca.2017.07.037
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II TrialJournal of Clinical Oncology, 2013
- Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancerJCI Insight, 2013
- Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell LinesCancer Biotherapy & Radiopharmaceuticals, 2013
- ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effectNature, 2012
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette TransportersCancer Research, 2010
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of EverolimusClinical Cancer Research, 2007
- Cancer's Molecular Sweet Tooth and the Warburg EffectCancer Research, 2006
- Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted TherapyClinical Cancer Research, 2006
- EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent MechanismsCancer Research, 2006
- Akt Stimulates Aerobic Glycolysis in Cancer CellsCancer Research, 2004